Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α2-Adrenoceptor Blocking Activity
Citations Over TimeTop 10% of 2004 papers
Abstract
The synthesis and pharmacology of a new series of 3-piperazinylmethyl-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles that combine central serotonin (5-HT) reuptake inhibition with alpha(2)-adrenoceptor blocking activity is described as potential antidepressants. Four compounds were selected for further evaluation, and the combination of both activities was found to be stereoselective, residing mainly in one enantiomer. Reversal of the loss of righting induced by the alpha(2)-agonist medetomidine in rats confirmed the alpha(2)-adrenoceptor blocking activity in vivo and also demonstrated CNS penetration. Antagonism of p-chloroamphetamine (pCA)-induced excitation as well as blockade of the neuronal 5-HT depletion induced by p-CA administration in rats confirmed their ability to block the central 5-HTT, even after oral administration. Replacement of the oxygen atom at the 5-position of the tricyclic scaffold by a nitrogen or a carbon atom, as well as O-substitution at position 7, led also to active compounds, both in vitro and in vivo.
Related Papers
- → In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from Releasing Agents: Sibutramine Is a Reuptake Inhibitor(1997)114 cited
- → Chapter 2 Recent Developments in Monoamine Reuptake Inhibitors(2007)22 cited
- → Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors(2013)9 cited
- → Development of norepinephrine transporter reuptake inhibition assays using SK-N-BE(2)C cells(2018)3 cited
- → Interactions of Serotonin Reuptake Inhibitors With Tricyclic Antidepressants(1995)25 cited